Invitation Letter

2025/05/09

Beilu pharma is delighted to to extend a warm invitation to you to make an appointment in CPHI China June 24-26 at Shanghai.

Our Booth Number is E3A49.

Related News

Foreign Journalists Visit Beilu Pharmaceutical to Learn about Beijing's Green Development
August 14, 2023On August 9, Beijing Foreign Affairs Office and Miyun District jointly organized 76 foreign journalists from 66 countries, including Brazil, Russia, Thailand and Saudi Arabia, to go into Miyun Distric...view
New Specifications of Repaglinide Tablets from Beilu Pharma Were Deemed to Have Passed the Generic Drugs Quality and Efficacy Consistency Evaluation
December 20, 2021Now, our company received the Notification of Approval of Supplementary Application for Repaglinide Tablets issued by the State Medical Products Administration (Notification No. : 2021 B04618). After ...view
Beilu Pharmaceutical has been awarded "Beijing Advanced Unit of Adverse Drug Reactions Daily Monitoring" for 4 consecutive years.
August 4, 2022Recently, the Beijing Municipal Drug Administration and Beijing Municipal Health Commission issued the "notice on the outstanding Performance of units and individuals in the monitoring of adverse...view
CPhl China 2023 Invitation
April 20, 2023view
Beilu Pharma's Iopamidol Injection passed the Consistency Evaluation of Generic Drugs!
February 18, 2022Recently, Beilu Pharma received the “Approval Notice for Supplementary Drug Application” for two specifications of Iopamidol Injection issued by the NMPA (Notice No.: 2022B00641, 2022B00642). Follow...view
Iohexol from Beilu Pharma's holding subsidiary Zhejiang Hichi Pharmaceutical Corporation Limited has been registered with CDSCO
March 7, 2023Recently, Zhejiang Haichang Pharmaceutical Co., Ltd., a subsidiary of Beijing Beilu Pharmaceutical Co., Ltd., received a registration certificate for its active pharmaceutical ingredient product from ...view

Invitation Letter

Foreign Journalists Visit Beilu Pharmaceutical to Learn about Beijing's Green Development

New Specifications of Repaglinide Tablets from Beilu Pharma Were Deemed to Have Passed the Generic Drugs Quality and Efficacy Consistency Evaluation

Beilu Pharmaceutical has been awarded "Beijing Advanced Unit of Adverse Drug Reactions Daily Monitoring" for 4 consecutive years.

CPhl China 2023 Invitation

Beilu Pharma's Iopamidol Injection passed the Consistency Evaluation of Generic Drugs!

Iohexol from Beilu Pharma's holding subsidiary Zhejiang Hichi Pharmaceutical Corporation Limited has been registered with CDSCO